Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Acquires 35,000 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour bought 35,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was bought at an average price of $3.30 per share, for a total transaction of $115,500.00. Following the purchase, the chief executive officer owned 3,183,000 shares in the company, valued at approximately $10,503,900. This represents a 1.11% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Neonc Technologies Stock Down 12.4%

Shares of NTHI stock opened at $3.31 on Wednesday. Neonc Technologies Holdings, Inc. has a one year low of $3.01 and a one year high of $12.99. The company’s 50-day simple moving average is $4.04 and its 200-day simple moving average is $5.27.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

Trending Headlines about Neonc Technologies

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: Company executives continued buying shares. CEO Amir F. Heshmatpour purchased a combined 87,000 shares across transactions dated September 11, 14 and 15, while CEO Thomas C. Chen bought 10,798 shares and CFO Keithly Garnett purchased 257 shares. The purchases signal that management believes the shares may be undervalued and provide a potential confidence boost for investors. SEC insider purchase filing
• Positive Sentiment: NeOnc is advancing NEO100 toward another regulatory review, while its targeted-delivery platform and oncology programs remain central to the investment story. The company’s lead program is in Phase 2a development for glioblastoma, creating potential upside if clinical and regulatory milestones are achieved. NeOnc regulatory update
• Neutral Sentiment: Analyst opinions remain mixed. Several firms maintain Buy ratings and high price targets, but other services have issued Sell ratings; the reported consensus is Hold. These targets may be especially speculative given NeOnc’s early-stage clinical profile.
• Negative Sentiment: The company recently reported a quarterly loss of $0.58 per share, substantially worse than the consensus loss estimate of $0.12. The earnings miss reinforces concerns about cash usage and the time required to commercialize its therapies.
• Negative Sentiment: Recent financing involving healthcare-focused institutions may provide capital to advance NEO100, but issuing or selling additional shares can dilute existing shareholders. Investors are also likely cautious because NTHI remains well below its longer-term moving averages and has experienced elevated trading volume.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NTHI. BTIG Research reissued a “buy” rating and set a $15.00 target price on shares of Neonc Technologies in a report on Tuesday, September 8th. Weiss Ratings raised shares of Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 31st. Alliance Global Partners started coverage on shares of Neonc Technologies in a research note on Tuesday, May 19th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, Wall Street Zen cut shares of Neonc Technologies from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Neonc Technologies has an average rating of “Hold” and a consensus price target of $16.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new stake in Neonc Technologies in the second quarter valued at $126,000. BlackRock Inc. bought a new position in shares of Neonc Technologies during the second quarter worth about $815,000. Westmount Partners LLC lifted its position in Neonc Technologies by 355.2% in the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock valued at $893,000 after purchasing an additional 153,858 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in Neonc Technologies during the 2nd quarter valued at about $1,017,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.